Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Janet Strong

Nurse Practitioner Boise, ID Nurse Practitioner

NPI 1255418539 CMS profile 11125263

5985 W State St, Boise, ID 83703

Open in the dashboard

General payments

$5,710

361 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Janet Strong of Boise, ID is reported in the CMS Open Payments database as having received $5,710 across 361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $1,782 104
2022 General $1,706 112
2021 General $2,203 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet Strong
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Janet Strong were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Janet Strong Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,203 $135 $40–$426 $132
2022 $1,706 $152 $48–$470 $149
2023 $1,782 $166 $54–$529 $160
2024 $19 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $937 68 payments
  2. Supernus Pharmaceuticals, Inc. $702 45 payments
  3. Otsuka America Pharmaceutical, Inc. $680 42 payments
  4. Janssen Pharmaceuticals, Inc $452 25 payments
  5. ITI, Inc. $439 31 payments
  6. Lundbeck LLC $390 22 payments
  7. Teva Pharmaceuticals USA, Inc. $380 29 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $303 20 payments
  9. Alkermes, Inc. $291 19 payments
  10. Vanda Pharmaceuticals Inc. $243 11 payments
  11. Other $895 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $5,634 357 payments
  2. Education $76 4 payments
Products named General payments · program years 2021–2024
  1. VRAYLAR $891 66 payments
  2. QELBREE $702 45 payments
  3. CAPLYTA $439 31 payments
  4. INVEGA SUSTENNA $380 20 payments
  5. REXULTI Psychiatry $292 16 payments
  6. ARISTADA Cns $291 19 payments
  7. ARISTADA Cns $291 19 payments
  8. REXULTI Psychiatry $283 15 payments
  9. AUSTEDO $277 20 payments
  10. ARISTADA INITIO $256 17 payments
  11. Other $3,210 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record